News & Updates
Showing Obstetrics & Gynaecology articles
Showing

Pyrotinib + capecitabine extends OS in metastatic breast cancer
Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.

Prepregnancy adhrence to plant-based diets lowers risk of gestational diabetes mellitus
Women with greater adherence to a healthful plant-based diet before pregnancy appear to have a reduced risk of gestational diabetes mellitus (GDM), suggests a recent study. On the other hand, adherence to an unhealthful plant-based diet is not associated with GDM risk.

Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.

Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer
The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.




